BioSpace News Archive

Rivus Pharmaceuticals Inc., a biopharmaceutical company dedicated to improving cardio-metabolic health, announced positive results from a Phase 2a clinical trial of HU6 in obese participants with elevated liver fat.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 9:20 a.m. ET.

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference.

Mevion Medical Systems and Proton International announce the selection of the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) to equip the UT Health San Antonio Proton Therapy and Research Center.

Silence Therapeutics today announced positive topline results in its phase 1 single-ascending dose study of SLN360, an siRNA targeting lipoprotein(a) (“Lp(a)”), in healthy adults with high Lp(a).

STAAR Surgical Company today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close.

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical trial of AVR-RD-04.

Seismic Therapeutic, Inc. today announced its launch and financing of $101 million.

Ventus Therapeutics , Inc. announced today the closing of a $140 million Series C financing.

Synthetic Biologics, Inc. today announced that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022.